Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyeon, Jae Wook | - |
dc.contributor.author | Kim, Su Yeon | - |
dc.contributor.author | Lee, Jeongmin | - |
dc.contributor.author | Park, Jun Sun | - |
dc.contributor.author | Hwang, Kyu Jam | - |
dc.contributor.author | Lee, Sol Moe | - |
dc.contributor.author | An, SeongSoo A. | - |
dc.contributor.author | Lee, Myung Koo | - |
dc.contributor.author | Ju, Young Ran | - |
dc.date.available | 2020-02-28T07:44:28Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2015-10-28 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10023 | - |
dc.description.abstract | The 14-3-3 protein has been used as a biomarker for the diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD). However, weakly positive 14-3-3 leads to false positive results and an incorrect diagnosis. We attempted to use quantitative data for tau protein to provide an accurate diagnosis based on weak 14-3-3 protein. Sixty-two patients with sCJD, including pathologically confirmed, clinically definite, and probable cases, and 89 non-CJD patients were investigated based on a Korean population. Among them, 20 sCJD and 14 non-CJD showed weakly positive 14-3-3. The total tau (t-tau) and phosphorylated tau (p-tau) protein levels were measured by ELISA, and the p-tau to t-tau ratio (p/t ratio) was calculated. The combined use of the 14-3-3 protein assay, t-tau levels, and p/t ratio improved the specificity of diagnosis compared with the use of the 14-3-3 protein assay alone (47% for 14-3-3 alone; 85.94% for 14-3-3 combined with t-tau; 90.62% for 14-3-3 combined with the p/t ratio). In addition, 18 of 20 sCJD and 12 of 14 non-CJD who were weakly positive for 14-3-3 were positive for the p/t ratio and negative for the p/t ratio, respectively. When used in combination with the 14-3-3 protein, the tau protein is useful as a biomarker for the precise diagnosis of sCJD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.subject | CEREBROSPINAL-FLUID | - |
dc.subject | CSF | - |
dc.subject | 14-3-3-PROTEIN | - |
dc.subject | PHOSPHORYLATION | - |
dc.subject | SENSITIVITY | - |
dc.subject | MARKERS | - |
dc.subject | RATIO | - |
dc.subject | ASSAY | - |
dc.title | Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000363519500001 | - |
dc.identifier.doi | 10.1038/srep15283 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.5 | - |
dc.identifier.scopusid | 2-s2.0-84945910798 | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 5 | - |
dc.contributor.affiliatedAuthor | An, SeongSoo A. | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | CEREBROSPINAL-FLUID | - |
dc.subject.keywordPlus | CSF | - |
dc.subject.keywordPlus | 14-3-3-PROTEIN | - |
dc.subject.keywordPlus | PHOSPHORYLATION | - |
dc.subject.keywordPlus | SENSITIVITY | - |
dc.subject.keywordPlus | MARKERS | - |
dc.subject.keywordPlus | RATIO | - |
dc.subject.keywordPlus | ASSAY | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.